We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology Newsfeed
  • Blog
  • Events
  • Popular
  • About
  • Login
  • Register
  • Your Basket
  • Blog
  • Events
  • Popular
  • About
  • Login
  • Register
  • Newsfeed
  • Navigator
  • Hubs
  • Webinars
  • Store
  • Analytics
  • Insights
  • Track
  • Create
  • Newsfeed
  • Navigator
  • Hubs
  • Webinars
  • Store
  • Analytics
  • Insights
  • Track
  • Create
Back Forward
  • Save & file
  • View original
  • Forward
  • Share
    • Facebook
    • Twitter
    • Google Plus
    • Linked In
  • Follow
    Please login to follow content.
  • Like

add to folder:

  • My saved (default)
  • Read later

Register now for your free, tailored, daily legal newsfeed service.

Questions? Please contact customerservices@lexology.com

Register

CETA update – our previously reported “good news” is maintained

Baker McKenzie

To view this article you need a PDF viewer such as Adobe Reader. Download Adobe Acrobat Reader

If you can't read this PDF, you can view its text here. Go back to the PDF .

Canada, European Union November 11 2014

The Pharmaceutical and Healthcare Newsletter of Baker & McKenzie’s North American Intellectual Property Practice Group
CETA Update – Our Previously
Reported “Good News” is
Maintained
Kamleh Nicola
On September 26, 2014, the Government of Canada released the consolidated text
for the Canada EU Comprehensive Economic and Trade Agreement (CETA). After
much delay (negotiations commenced in 2009), which included a large portion
of the text leaked to the public this past August, the full text as it presently
exists is finally available for review. As we previously reported, there were a few
nuggets that were the topic of negotiation for the pharmaceutical and life science
industries. We are now in a position to assess whether those nuggets have been
maintained in whole or in part.
Will Innovators Finally Have a Meaningful Right of Appeal
Under PMNOC?
The short answer is: "We think so". The current regime under the Patented
Medicines (Notice of Compliance) Regulations (PMNOC Regulations), provides
generic manufacturers with an effective right of appeal where the court rules
in favour of the innovator. There is no corresponding right of appeal for the
innovator. Once a court rules in favour of the generic, the Notice of Compliance
(marketing authorization) issues to the generic very quickly (often within days),
thereby rendering any possible appeal by the innovator as moot. However, the
CETA text is vague and simply directs that each of Canada and the EU "shall
ensure that all [patent linkage] litigants are afforded equivalent and effective
rights of appeal". No further clarity is provided as to how an innovator's right of
appeal shall be implemented under the PMNOC Regulations, or its impact on
the 24-month statutory stay mechanism. Whether the current regime of dual
litigation will be eliminated, is also unclear.
Will Patent Term Extension Finally Arrive to Canadian Shores?
"Yes" is the short answer to this question. A single period of patent term
extension (referred to as sui generis protection in the CETA text) may be obtained
regardless of the number of patents that protects the drug product. This will
provide an innovator with the opportunity to seek additional protection for the
period that elapses from the date upon which a patent application was filed and
RxAnalysis is the Pharmaceutical and Healthcare Newsletter of Baker & McKenzie’s North American Intellectual Property Practice Group
The Pharmaceutical and Healthcare Newsletter of Baker & McKenzie’s North American Intellectual Property Practice Group
the date of issuance of the first market authorization, minus 5 years. This
effectively restores lost patent term due to the length of time necessary to
obtain regulatory approval. However, this protection will not apply retroactively
to drug products already approved and on the market.
While the CETA text provides the length of this patent term extension shall not
be less than 2 years or greater than 5 years, Canada has announced that it will
provide up to 2 years. This additional period of protection will commence upon
expiry of the patent. Where more than one patent covers the drug product, then
the patent holder will have the opportunity to select the date upon which the
patent term extension commences. Where multiple patent holders exist, the
term will be established upon agreement.
An exception has been negotiated to enable the export of generic drug products
during the period of additional protection. Canada has said that this "will
temper the impact on the generic industry and its competitiveness in the
important United States market".
Will Data Protection Be Extended By 2 Years?
The answer here is a categorical "no". Canada rejected the EU's request that
the term of data protection be extended to 10 years. However, Canada did affirm
its commitment to the current regime of data protection, which provides a "no
filing" period for generic drug regulatory applications of 6 years and a 2 year "no
marketing" period during which a generic cannot sell its drug product.
Conclusion
Overall, the commitments summarized above should benefit the innovative
industry and finally provide alignment with other G7 nations in key areas such
as providing innovators with a meaningful right of appeal and patent term
restoration. Canada is assuming that CETA will be ratified in 2015. Regulatory
amendment to implement these changes will follow. We will continue to
monitor this situation and report on further CETA happenings.
Kamleh Nicola is a lawyer
practising in the Toronto
office of Baker & McKenzie in
pharmaceutical litigation and
related areas.

Baker McKenzie - Kamleh J. Nicola
Back Forward
  • Save & file
  • View original
  • Forward
  • Share
    • Facebook
    • Twitter
    • Google Plus
    • Linked In
  • Follow
    Please login to follow content.
  • Like

add to folder:

  • My saved (default)
  • Read later

Filed under

  • Canada
  • European Union
  • Healthcare & Life Sciences
  • Patents
  • Baker McKenzie

Tagged with

  • CETA

Popular articles from this firm

  1. Mandatory Sexual Harassment Training Comes To New York *
  2. Take A Break To Remember Your Meal And Rest Period Obligations Under California Law *
  3. New obligation for Spanish companies to disclose their ultimate beneficial owners *
  4. Russia Proposes Harsh New Counter-Sanctions *
  5. The Crypto Valleys: The Regulatory Battle to Become the Global Hub of ICOs *

If you would like to learn how Lexology can drive your content marketing strategy forward, please email enquiries@lexology.com.

Send to Create
Powered by Lexology

Related topic hubs

  1. European Union
  2. Canada
  3. Patents
  4. Healthcare & Life Sciences

Lexology Navigator Q&A

Compare jurisdictions: Patents

  1. Canada
  2. Romania
  3. USA
  4. More...
Don Sangster
Legal Department Administrator
Jovian Capital Corporation
What our clients say

”Lexology is a useful and informative tool. I keep copies of relevant articles and often forward them to colleagues. Although I do not know all of the authors/firms, by reading their articles I do gain an understanding of their appreciation of a topic, and should the need arise I would not hesitate to contact them on those topics.”

Back to Top
  • RSS feeds
  • Contact
  • Submissions
  • About
  • Terms of use
  • Cookies
  • Disclaimer
  • Privacy policy
  • Login
  • Register
  • Follow on Twitter
  • Search
Globe Business Media Group

© Copyright 2006 - 2018 Globe Business Media Group